An interventional study of Intervention via mobile application in Schizophrenia and Schizo Affective Disorder, sponsored by University of Pittsburgh. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Supportive care
Among 22 studies in Schizophrenia by University of Pittsburgh — 2 open to participants now, 4 under way, none of them phase 3. Schizophrenia · University of Pittsburgh.
Among the 22 studies in Schizophrenia by University of Pittsburgh, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2027, is one of 11 with no phase, and was the 19th registered.
3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.
Browse Schizophrenia studies →2 of the 22 studies in Schizophrenia by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:
University of Pittsburgh · Sites in India
By country, each count listing its studies:
Of the 331 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 257 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2027.
This study's planned enrollment of 44 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.
Median enrollment 69 across the 20 interventional studies, 121 across the 2 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
1 of the studies in Schizophrenia by University of Pittsburgh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04143126University of PittsburghPromoting Activity and Cognitive Enrichment in Schizophrenia (PACES) | 2027-06-30 |
Among the 22 studies in Schizophrenia by University of Pittsburgh, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A new mental health application will be developed for persons with schizophrenia and schizoaffective disorder. The aim is to look at whether it is feasible to use a mobile health application for improving medication adherence in persons with schizophrenia and schizoaffective disorder and whether it is acceptable to that population.
Many interventions have been tried to improve the medication adherence of patients with schizophrenia. Individualized interventions using like setting alarms and using checklists have shown significant improvement in compliance with the medications. In the era of mobile applications most of the persons use mobile applications for multiple purposes, which have the potential to influence the life of a person in many ways. A meta-analysis conducted in 2016 showed that 66.4% of psychotic patients owned a mobile phone. A study conducted in North India found that 84.4% of patients with severe mental disorders owned a mobile phone. So if used properly it can also help in improving the life of a person with SZ.
Many mobile applications have been used to improve medication compliance in general. But only a few mobile applications have specifically focused the persons with schizophrenia. Very few studies have investigated the efficacy of mobile applications to improve medication adherence in patients with schizophrenia. This study will be assessing the feasibility of developing a mobile application and using the application for improving compliance of medications in persons with schizophrenia and schizoaffective disorder.
Primary aims:
Primary Objectives:
Secondary Objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
Behavioral: Intervention via mobile application
Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
Feasibility of Mobile app
To assess the feasibility and the acceptability with a mobile mental health application for medication adherence in persons with SZ and schizoaffective disorder using Acceptability Questionnaire. The scale ranges from 0 to 50.
Time frame: Baseline and after three months
Acceptibility of Mobile app
To assess the feasibility and the acceptability with a mobile mental health application for medication adherence in persons with SZ and schizoaffective disorder using Perception of treatment Acceptability scale (Score (0-5) 0= Not at all 5 =very much). Ranges from 0 to 50. )
Time frame: Baseline and after three months
Adherence to medication
To compare the Medication adherence rating scale scores before and after using mental health application for changing medication adherence in persons with schizophrenia and schizoaffective disorder
Time frame: Baseline and after three months
Plan to share: Yes — Individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol, Statistical analysis plan
Time frame: One year after publication of this study.
Access criteria: For individual participant data, meta-analysis.
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for May 2028, 11 months later.
Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 11 months is below that.
Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.